Assessment of the COVID-19 vaccine market landscape in 2021 relative to challenges in low- and middle-income countries

References

• Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, Hasell J, Macdonald B, Dattani S, Roser M. Coronavirus pandemic (COVID-19). https://ourworldindata.org/coronavirus.
   Google Scholar
• World Health Organization. COVID-19 vaccine tracker and landscape. [accessed 2021 Dec 24]. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
   Google Scholar
• World Health Organization. COVID-19 vaccines with WHO emergency use listing. [accessed 2022 Aug 7]. https://extranet.who.int/pqweb/vaccines/vaccinescovid-19-vaccine-eul-issued.
   Google Scholar
• CEPI, GAVI, UNICEF, WHO. COVAX global supply forecast: December 14, 2021 update. December 14, 2021. 2021.
   Google Scholar
• CEPI, GAVI, UNICEF, WHO. COVAX global supply forecast: April 7, 2021 update. April 7, 2021 2021.
   Google Scholar
• COVAX announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021. 2020 Dec 18 [accessed 2022 Mar 25]. https://www.who.int/news/item/18-12-2020-covax-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021.
   Google Scholar
• Chavda VP, Apostolopoulos V. Is booster dose strategy sufficient for omicron variant of SARS-CoV-2? Vaccines. 2022;10(3):1. doi:10.3390/vaccines10030367.
   Web of Science ®Google Scholar
• Kuhlmann C, Mayer CK, Claassen M, Maponga T, Burgers WA, Keeton R, Riou C, Sutherland AD, Suliman T, Shaw ML, et al. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. The Lancet. 2022 Feb 12;399(10325):625–10. doi:10.1016/S0140-6736(22)00090-3.
   PubMed Web of Science ®Google Scholar
• Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, Amoako DG, Everatt J, Bhiman JN, Scheepers C, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. The Lancet. 2022;399(10323):437–46. doi:10.1016/S0140-6736(22)00017-4.
   PubMed Web of Science ®Google Scholar
• Tian D, Sun Y, Xu H, Ye Q. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 omicron variant. J Med Virol. 2022 Feb 3.doi:10.1002/jmv.27643.
   Web of Science ®Google Scholar
• Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, Mizrahi B, Alroy-Preis S, Ash N, Milo R, et al. Protection of BNT162b2 vaccine booster against covid-19 in Israel. N Engl J Med. 2021 Oct 7;385(15):1393–400. doi:10.1056/NEJMoa2114255.
   PubMed Web of Science ®Google Scholar
• Li Y, Tenchov R, Smoot J, Liu C, Watkins S, Zhou Q. A comprehensive review of the global efforts on COVID-19 vaccine development. ACS Central Sci. 2021 Apr 28;7(4):512–33. doi:10.1021/acscentsci.1c00120.
   PubMed Web of Science ®Google Scholar
• Organization TWH. WHO target product profiles for COVID-19 vaccines. 2020. [accessed 2021 Apr 10]. https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines.
   Google Scholar
• Medicine UNLo. ClinicalTrials.gov. [accessed 2021 April 10]. https://clinicaltrials.gov/.
   Google Scholar
• UNICEF. COVID-19 Vaccine market dashboard. [accessed 2021 April 8]. https://www.unicef.org/supply/covid-19-vaccine-market-dashboard.
   Google Scholar
• Dellepiane N, Wood D. Twenty-Five years of the WHO vaccines prequalification programme (1987–2012): lessons learned and future perspectives. Vaccine. 2015 Jan 1;33(1):52–61. doi:10.1016/j.vaccine.2013.11.066.
   PubMed Web of Science ®Google Scholar
• Innovation CfB. Comparing centralized vs. distributed models of biologics manufacturing and supply for global health: a discussion of challenges and opportunities. 2017 May 26. [accessed 2022 Mar 12]. https://cbi.mit.edu/wp-content/uploads/2020/11/Scoping-Report-Global-Biologics-Supply.pdf.
   Google Scholar
• Kis Z, Kontoravdi C, Dey AK, Shattock R, Shah N. Rapid development and deployment of high-volume vaccines for pandemic response. J Adv Manuf Process. 2020 July 1;2(3):e10060. doi:10.1002/amp2.10060.
   PubMedGoogle Scholar
• Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, Teerawattananon Y, Jit M. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. The Lancet. 2021;397(10278):1023–34. doi:10.1016/S0140-6736(21)00306-8.
   PubMed Web of Science ®Google Scholar
• Figueroa JP, Bottazzi ME, Hotez P, Batista C, Ergonul O, Gilbert S, Gursel M, Hassanain M, Kim JH, Lall B, et al. Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics. The Lancet. 2021;397(10274):562–64. doi:10.1016/S0140-6736(21)00242-7.
   PubMed Web of Science ®Google Scholar
• Friede M, Palkonyay L, Alfonso C, Pervikov Y, Torelli G, Wood D, Kieny MP. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. Vaccine. 2011 Jul 1;29(Suppl 1):A2–7. doi:10.1016/j.vaccine.2011.02.079.
   PubMed Web of Science ®Google Scholar
• WHO. Emergency use listing procedure. 2020 December 14 [accessed 2022 Mar 11]. https://www.who.int/publications/m/item/emergency-use-listing-procedure.
   Google Scholar
• WHO. A framework for evaluating and publicly designating regulatory authorities as WHO-listed authority (WLA) interim list of national regulatory authorities. [accessed 2021 April 10]. http://www.who.int/medicines/regulation/wla_introduction/en/.
   Google Scholar
• Alliance GTV. Cold chain equipment optimisation platform. 2020. [accessed 2022 Mar 12]. https://www.gavi.org/sites/default/files/publications/Cold-chain-equipment-technology-guide.pdf.
   Google Scholar
• Kristensen DD, Lorenson T, Bartholomew K, Villadiego S. Can thermostable vaccines help address cold-chain challenges? Results from stakeholder interviews in six low- and middle-income countries. Vaccine. 2016;34(7):899–904. doi:10.1016/j.vaccine.2016.01.001.
   PubMed Web of Science ®Google Scholar
• Dean NE, Gsell P-S, Brookmeyer R, De Gruttola V, Donnelly CA, Halloran ME, Jasseh M, Nason M, Riveros X, Watson CH, et al. Design of vaccine efficacy trials during public health emergencies. Sci Transl Med. 2019;11(499):eaat0360. doi:10.1126/scitranslmed.aat0360.
   PubMed Web of Science ®Google Scholar
• Oh SS, Galanter J, Thakur N, Pino-Yanes M, Barcelo NE, White MJ, de Bruin DM, Greenblatt RM, Bibbins-Domingo K, Wu AHB, et al. Diversity in clinical and biomedical research: a promise yet to be fulfilled. PLoS Med. 2015;12(12):e1001918. doi:10.1371/journal.pmed.1001918.
   PubMed Web of Science ®Google Scholar
• WHO. Annex 1: WHO guidelines on clinical evaluation of vaccines: regulatory expectationS 2001. [accessed 2022 Mar 12]. https://www.who.int/biologicals/publications/clinical_guidelines_ecbs_2001.pdf?ua=1.
   Google Scholar
• Oloo P. A comparison of vaccine efficacy elements in advanced stage clinical trial protocols 2020 Nov 9 [accessed 2022 March 12]. https://epi.tghn.org/articles/comparison-vaccine-efficacy-elements-advanced-stage-clinical-trial-protocols/.
   Google Scholar
• Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discovery. 2018 Apr 1;17(4):261–279. doi:10.1038/nrd.2017.243.
   PubMed Web of Science ®Google Scholar
• Moore JP, Offit PA. SARS-CoV-2 vaccines and the growing threat of viral variants. JAMA. 2021;325(9):821–822. doi:10.1001/jama.2021.1114.
   PubMed Web of Science ®Google Scholar
• Kansteiner F. Emergent wins FDA all-clear to restart J&J COVID-19 vaccine production in baltimore. Fierce Pharma. Online at fiercepharma.com2021.
   Google Scholar
• CEPI G, UNICEF and WHO. COVAX global supply forecast: September 8, 2021 update. 2021.
   Google Scholar
• Plotkin S, Robinson JM, Cunningham G, Iqbal R, Larsen S. The complexity and cost of vaccine manufacturing - an overview. Vaccine. 2017;35(33):4064–71. doi:10.1016/j.vaccine.2017.06.003.
   PubMed Web of Science ®Google Scholar
• Staff BR. Active pharmaceutical ingredients: global markets. 2021.
   Google Scholar
• Paris C Supply-chain obstacles led to last month’s cut to Pfizer’s covid-19 vaccine-rollout target. The Wall Street Journal. 2022 Dec 3 [accessed 2022 Mar 10]. https://www.wsj.com/articles/pfizer-slashed-its-covid-19-vaccine-rollout-target-after-facing-supply-chain-obstacles-11607027787.
   Google Scholar
• MADE in America Act of 2020. H. R. 6930, 116th US congress 2d session sess. 2020 May 19. https://www.congress.gov/bill/116th-congress/house-bill/6930/text.
   Google Scholar
• Usher AD. South Africa and India push for COVID-19 patents ban. The Lancet. 2020 Dec 5;396(10265):1790–91. doi:10.1016/S0140-6736(20)32581-2.
   PubMed Web of Science ®Google Scholar
• Peacocke EF, Heupink LF, Frønsdal K, Dahl EH, Chola L. Global access to COVID-19 vaccines: a scoping review of factors that may influence equitable access for low and middle-income countries. BMJ Open. 2021 Sep 30;11(9):e049505. doi:10.1136/bmjopen-2021-049505.
   PubMed Web of Science ®Google Scholar
• Khan MI, Ikram A, Hamza HB. Vaccine manufacturing capacity in low- and middle-income countries. Bull World Health Organ. 2021;99(7):479. doi:10.2471/BLT.20.273375.
   PubMedGoogle Scholar
• Monitoring B. Covid: stalled Russian vaccines cause global anger. BBC. 2021 July 29 [accessed 2022 Mar 11]. https://www.bbc.com/news/world-europe-58003893.
   Google Scholar
• Moutinho S. Brazil gives Russian COVID-19 vaccine a chance, approving the import of limited doses. Science. Online at science.org2021.
   Google Scholar
• WHO. Suspension of supply of COVID-19 vaccine (COVAXIN®). 2022 Apr 2.
   Google Scholar
• WHO. Public statement for collaboration on COVID-19 vaccine development. 2020 Apr 13 [accessed 2022 Mar 11]. https://www.who.int/news/item/13-04-2020-public-statement-for-collaboration-on-covid-19-vaccine-development.
   Google Scholar
• Khadem Broojerdi A, Baran Sillo H, Ostad Ali Dehaghi R, Ward M, Refaat M, Parry J. The world health organization global benchmarking tool an instrument to strengthen medical products regulation and promote universal health coverage. Policy and practice reviews. Front Med. 2020 Aug 19;7. doi:10.3389/fmed.2020.00457.
   Web of Science ®Google Scholar
• Ndomondo-Sigonda M, Miot J, Naidoo S, Dodoo A, Kaale E. Medicines regulation in Africa: current state and opportunities. Pharmaceut Med. 2017;31(6):383–97. doi:10.1007/s40290-017-0210-x.
   PubMed Web of Science ®Google Scholar
• Guzman J, Connell E, Kikule K, Hafner T. The WHO global benchmarking Tool: a game changer for strengthening national regulatory capacity. BMJ Global Health. 2020;5(8):e003181. doi:10.1136/bmjgh-2020-003181.
   PubMed Web of Science ®Google Scholar
• Goldhill O We have enough covid vaccines for most of the world. But rich countries are stockpiling more than they need for boosters. STAT. 2021Dec 13 [accessed 2022 Mar 25]. https://www.statnews.com/2021/12/13/we-have-enough-covid-vaccines-for-most-of-world-but-rich-countries-stockpiling-more-than-they-need/.
   Google Scholar
• Stevis-Gridneff M E.U. will curb covid vaccine exports for 6 weeks. New York times. [accessed 2022 Mar 11]. https://www.nytimes.com/2021/03/23/world/europe/eu-curbs-vaccine-exports.html.
   Google Scholar
• Gettleman J, Schmall E, Mashal M India cuts back on vaccine exports as infections surge at home. New York times. [accessed 2022 Mar 11]. https://www.nytimes.com/2021/03/25/world/asia/india-covid-vaccine-astrazeneca.html.
   Google Scholar
• MacPherson A, Hutchinson N, Schneider O, Oliviero E, Feldhake E, Ouimet C, Sheng J, Awan F, Wang C, Papenburg J, et al. Probability of success and timelines for the development of vaccines for emerging and reemerged viral infectious diseases. Ann Intern Med. 2021 Mar 16;174(3):326–34. doi:10.7326/M20-5350.
   PubMed Web of Science ®Google Scholar
• Altimmune announces update on AdCOVID™ phase 1 clinical trial. Altimmune. 2021 June 29 [accessed 2022 Mar 12]. https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-update-adcovidtm-phase-1-clinical-trial.
   Google Scholar
• Aizenman N They desperately need COVID vaccines. So why are some countries throwing out doses? NPR. [accessed 2022 Mar 25]. https://www.npr.org/sections/goatsandsoda/2021/05/05/991684096/they-desperately-need-covid-vaccines-so-why-are-some-countries-throwing-out-dose.
   Google Scholar
• Cooper S, van Rooyen H, Wiysonge CS. COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines? Expert Rev Vaccines. 2021 Aug 3;20(8):921–33. doi:10.1080/14760584.2021.1949291.
   PubMed Web of Science ®Google Scholar
• Ball P. The lightning-fast quest for COVID vaccines — and what it means for other diseases. Nature. Online at nature.com2020.
   Google Scholar
• Kim JH, Hotez P, Batista C, Ergonul O, Figueroa JP, Gilbert S, Gursel M, Hassanain M, Kang G, Lall B, et al. Operation warp speed: implications for global vaccine security. Lancet Glob Health. 2021;9(7):e1017–e1021. doi:10.1016/S2214-109X(21)00140-6.
   PubMed Web of Science ®Google Scholar
• Center TG The Russian direct investment fund (RDIF).
   Google Scholar
• Blankenship K. BioNtech, CureVac bag $745M in German funding for COVID-19 vaccine hopefuls. Updated September 15, 2020 [accessed 2022 Mar 10]. https://www.fiercepharma.com/manufacturing/biontech-curevac-bag-745m-german-funding-for-covid-19-vaccine-hopefuls#: :text=In%20order%20to%20get%20both,their%20respective%20COVID%2D19%20candidates.
   Google Scholar
• CEPI. Our portfolio. [accessed 2022 Mar 10]. https://cepi.net/research_dev/our-portfolio/.
   Google Scholar
• Drain PK, Parker RA, Robine M, Holmes KK, Murthy S. Global migration of clinical research during the era of trial registration. Plos One. 2018;13(2):e0192413. doi:10.1371/journal.pone.0192413.
   PubMed Web of Science ®Google Scholar
• Ramanan M, Tong SYC, Kumar A, Venkatesh B. Geographical representation of low- and middle-income countries in randomized clinical trials for COVID-19. JAMA Network Open. 2022;5(2):e220444. doi:10.1001/jamanetworkopen.2022.0444.
   PubMed Web of Science ®Google Scholar